Literature DB >> 28702400

Sarcomatous transformation of a hemosiderotic fibrohistiocytic lipomatous tumor: a case report.

Renata Margarida Etchebehere1, Elia Cláudia Souza Almeida1, Carlos David Teixeira Santos2, Adilha Misson Rua Micheletti1, Antônio Sebastião Leitão1.   

Abstract

Hemosiderotic fibrohistiocytic lipomatous tumors are rare neoplasms that were first described in 2000. Initially considered a benign lipotamous lesion of the soft tissues, nowadays they are considered to be a locally aggressive tumor. They occur mainly in the foot and ankle of women in their fifth and sixth decades, although they may be found in any place in the lower limbs and, more rarely, in other parts of the body. Histologically, hemosiderotic fibrohistiocytic lipomatous tumors consist of a mixture of mature adipose tissue, fusiform cell fascicles, macrophages that often contain cytoplasmic hemosiderin, mononuclear inflammatory infiltrate, and stroma that may be focally myxoid. Local recurrence is observed in nearly one-third of all cases. There is no consensus in the literature whether this tumor is a part of a spectrum that comprises pleomorphic hyalinizing angiectatic tumors and myxoinflammatory fibroblastic malignant tumors, or if it is an independent entity. The authors report a case of a neoplasia after a diagnosis of a hemosiderotic fibrohistiocytic lipomatous tumor in a 38-year-old woman, with two recurrences and later sarcomatous transformation. An immunohistochemical study indicated myofibroblastic differentiation of a malignant neoplasm. To the best of the authors' knowledge, there are only few reported cases of malignant transformation in hemosiderotic fibrohistiocytic lipomatous tumors.

Entities:  

Keywords:  Adipose tissue; Connective tissue; Hemosiderin; Histiocytes; Sarcoma

Year:  2016        PMID: 28702400      PMCID: PMC5497010          DOI: 10.1016/j.rboe.2016.11.002

Source DB:  PubMed          Journal:  Rev Bras Ortop        ISSN: 2255-4971


Introduction

Hemosiderotic fibrohistiocytic lipomatous tumor (HFLT) is a rare neoplasm that was initially thought to be a reactive process secondary to trauma or an excessive tissue response to chronic venous stasis, which would stimulate the proliferation of elements seen in the lesion. Browne and Fletcher (2006) published a classic review of this tumor in which defined the clinical and histological characteristics. Initially, HFLT was believed to be a benign lipomatous neoplasm. The contemporary understanding is that HFLT is an unencapsulated, locally aggressive neoplasm that is composed of adipocytes, hemosiderin-laden spindle cells and macrophages, as well as scattered chronic inflammatory cells. The commonest site for HFLT is the dorsum of the foot, followed by other ankle and foot sites, the dorsum of the hand, and, finally, the calf, thigh, and cheek. HFLT is most frequently found in women in their fifth or sixth decade of life.1, 2, 3, 4, 5, 6 Radiologic images of the lesion reveal adipose tissue, often with septation, and features mimicking lipoma or low-grade sarcoma. Clinical and pathological features of HFLT are similar to those of pleomorphic hyalinizing angiectatic tumor (PHAT) and myxoinflammatory fibroblastic malignant tumor (MIFS), leading authors to speculate that HFLT may be a part of a spectrum involving these two other tumor types.8, 9, 10 HFLT does not produce metastases and is of uncertain lineage according to the soft-tissue tumor classification system of the World Health Organization. There are few reports of the malignant transformation of HFLT into MIFS.9, 10 Herein, we report a published case of a lesion that had previously been diagnosed, according to its morphological and by immunohistochemical (IHC) features, as HFLT. The lesion recurred twice and later showed malignant transformation to a low-grade unclassified pleomorphic sarcoma, with an IHC study suggesting myofibroblastic differentiation.

Case report

This case report was approved by the Ethics Committee at a tertiary public hospital. A 38-year-old female patient came to our clinic in December of 2010. She complained of a painful lesion in the back area of her left thigh, in the vicinity of prior tumor surgical resections (performed in September of 2006 and January of 2008). Previous resections led to a diagnosis of HFLT, based on morphological examination and complementary IHC study. The prior biopsies were reviewed, and the diagnosis was maintained. This case of HFLT has been previously reported in the literature. Magnetic resonance imaging showed a heterogeneous lesion with expansive growth and enhancement. Imaging suggested compromise to the muscle groups and subcutaneous tissues of the distal third of the left thigh, associated with an osteolytic lesion in the cortical region of the middle third of the left femur. Tumor resection was performed, and two roughly ovoid fragments of black-yellow and elastic tissue were obtained for histological evaluation. Tissues had hemorrhagic foci jointly measuring 22 cm × 18 cm × 11 cm and weighing 485 g. Microscopy showed an infiltrative, pleomorphic malignant neoplasm, with irregular edges in the soft tissues and variable cellularity. The neoplasm was comprised of round, oval, and fusiform cells, with hyperchromatic nuclei, sometimes bizarre and eosinophilic cytoplasms, and rare mitotic figures, compatible with sarcomatous transformation of the HFLT. We also noted areas with mature and often histiocytic adipose tissue containing hemosiderin (Fig. 1). This finding suggested that these were areas of a residual HFLT. No necrotic foci were visible.
Fig. 1

(A) Hemosiderotic fibrohistiocytic lipomatous tumors (HFLT) area (hematoxylin–eosin – HE, 100×); (B) malignant transformation area of HFLT showing increased cellularity and nuclear pleomorphism (HE, 100×); (C) nuclear atypia in the malignant transformation area of HFLT (HE, 400×).

(A) Hemosiderotic fibrohistiocytic lipomatous tumors (HFLT) area (hematoxylin–eosin – HE, 100×); (B) malignant transformation area of HFLT showing increased cellularity and nuclear pleomorphism (HE, 100×); (C) nuclear atypia in the malignant transformation area of HFLT (HE, 400×). On IHC analysis, the lesion was focally positive for smooth muscle actin and desmin, but negative for S100 protein and CD34, suggesting myofibroblastic differentiation of the sarcomatous component. A cell proliferation index of approximately 5% (Ki 67) was observed. Amputation was proposed to the patient, who refused this treatment and underwent chemotherapy and radiotherapy at other hospital.

Discussion

We compared findings from the previous resections, which yielded a diagnosis of HFLT, with the current morphology, which exhibited malignant features. This comparison allowed us to conclude that the lesion had undergone malignant transformation to a low-grade unclassified pleomorphic sarcoma, with IHC features suggesting myofibroblastic differentiation. The presence of areas with a benign pattern similar to the initial lesion intermixed with pleomorphic and infiltrative areas, as well as the proliferative index, reinforced this conclusion. Reports have described the presence of gene rearrangements in tumors showing mixed features, which strongly suggested a relationship of HFLT with PHAT and MIFS. Previous authors have concluded that HFLT, PHAT, and MIFS represent morphologic variants of a single entity, in which only the later has acquired the capacity to metastasize.3, 8, 9 One histological study suggested that most, if not all, tumors diagnosed as PHATs might actually represent examples of MIFS with aberrant angiectatic hyalinized vessels. Furthermore, the vascular changes in PHAT may represent only a histologic pattern and not a true neoplasm. Thus, MIFS and most cases of PHAT may represent different morphologic manifestations of a single entity. In this report, we present a case of HFLT with malignant transformation. The tumor retained areas similar to the original tumor, reinforcing the possibility that this entity is part of a spectrum of lesions with the potential for malignant evolution. After surgical resection of HFLT, patients should undergo rigorous and regular follow-up because of the possibility of sarcomatous transformation.

Conflicts of interest

The authors declare no conflicts of interest.
  9 in total

1.  Pleomorphic hyalinizing angiectatic tumor revisited: all tumors manifest typical morphologic features of myxoinflammatory fibroblastic sarcoma, further suggesting 2 morphologic variants of a single entity.

Authors:  Michael Michal; Dmitry V Kazakov; Ladislav Hadravský; Abbas Agaimy; Marián Švajdler; Naoto Kuroda; Michal Michal
Journal:  Ann Diagn Pathol       Date:  2015-10-29       Impact factor: 2.090

2.  Radiological imaging features and clinicopathological correlation of hemosiderotic fibrolipomatous tumor: experience in a single tertiary cancer center.

Authors:  Dearbhail O'Driscoll; Edward Athanasian; Meera Hameed; Sinchun Hwang
Journal:  Skeletal Radiol       Date:  2014-12-21       Impact factor: 2.199

Review 3.  Case report: hemosiderotic fibrohistiocytic lipomatous lesion: a clinicopathologic characterization.

Authors:  Vincent M Moretti; John S J Brooks; Christian M Ogilvie
Journal:  Clin Orthop Relat Res       Date:  2010-02-02       Impact factor: 4.176

4.  Haemosiderotic fibrolipomatous tumour (so-called haemosiderotic fibrohistiocytic lipomatous tumour): analysis of 13 new cases in support of a distinct entity.

Authors:  T-J Browne; C D M Fletcher
Journal:  Histopathology       Date:  2006-03       Impact factor: 5.087

5.  Haemosiderotic fibrohistiocytic lipomatous lesion/tumour of the foot: MRI and histopathology.

Authors:  Andrew T West; Andoni P Toms; Joseph Murphy; Mohammed Sultan
Journal:  Skeletal Radiol       Date:  2007-10-30       Impact factor: 2.199

6.  Cytogenetic analysis of a hemosiderotic fibrolipomatous tumor.

Authors:  George R Wettach; Luke J Boyd; Helen J Lawce; R Ellen Magenis; Atiya Mansoor
Journal:  Cancer Genet Cytogenet       Date:  2008-04-15

Review 7.  Hemosiderotic fibrohistiocytic lipomatous lesion: case report and review of the literature.

Authors:  Antônio Roberto Oliveira Ramalho; Marcella Nara Nunes; Sheila Jorge Adad; Sebastião Almeida Leitão; Adilha Misson Rua Micheletti
Journal:  Sao Paulo Med J       Date:  2009       Impact factor: 1.044

8.  TGFBR3 and MGEA5 rearrangements in pleomorphic hyalinizing angiectatic tumors and the spectrum of related neoplasms.

Authors:  Jodi M Carter; William R Sukov; Elizabeth Montgomery; John R Goldblum; Steven D Billings; Karen J Fritchie; Andrew L Folpe
Journal:  Am J Surg Pathol       Date:  2014-09       Impact factor: 6.394

9.  Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions.

Authors:  Karolin H Hallor; Raf Sciot; Johan Staaf; Markus Heidenblad; Anders Rydholm; Henrik Cf Bauer; Kristina Aström; Henryk A Domanski; Jeanne M Meis; Lars-Gunnar Kindblom; Ioannis Panagopoulos; Nils Mandahl; Fredrik Mertens
Journal:  J Pathol       Date:  2009-04       Impact factor: 7.996

  9 in total
  1 in total

1.  Rapidly fatal SMARCA4-deficient undifferentiated sarcoma originating from hybrid hemosiderotic fibrolipomatous tumor/pleomorphic hyalinizing angiectatic tumor of the foot.

Authors:  Abbas Agaimy; Norbert Meidenbauer; William R Sukov; Robert Stoehr; Michael Vieth; Frank Roemer; Robert Grützmann; Andrew L Folpe
Journal:  Virchows Arch       Date:  2021-08-14       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.